Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: A retrospective study of the clinical trials committee of the British Society of Blood & Marrow Transplantation (BSBMT)

Bone Marrow Transplantation

Volumn 36, Issue 12, 2005, Pages 1065-1069

  Cummins, M ^a   Cwynarski, K ^b   Marktel, S ^b   Dazzi, F ^b   Cavenagh, J ^c   Clark, R E ^d   Holyoake, T L ^e   Milligan, D ^f   Parker, A ^e   Russell, N H ^g   Marks, David I ^a,h  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^e GLASGOW ROYAL INFIRMARY   (United Kingdom)

^f BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^g NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^h UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Chronic myeloid leukaemia; Donor lymphocyte infusion; Imatinib mesylate; Relapse; Stem cell transplantation

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYUREA; IMATINIB; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; CYTOGENETICS; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; HEALTH CARE FACILITY; HEALTH CARE ORGANIZATION; HEMATOLOGY; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVING DONOR; LYMPHOCYTE TRANSFUSION; MALE; MANAGED CARE; MOLECULAR BIOLOGY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED KINGDOM; WHOLE BODY RADIATION;

ADULT; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG THERAPY; ENZYME INHIBITORS; FEMALE; GREAT BRITAIN; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; LYMPHOCYTES; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 30544445943     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705180     Document Type: Article

References (16)

1. Apperley JF, Jones L, Hale G et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1986; 1: 53-66.
2. Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukaemia Working Party. European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087-1092.
3. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
4. Dazzi F, Szydlo RM, Cross NC et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96: 2712-2716.
5. van Rhee F, Lin F, Cullis JO et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377-3383.
6. Sehn LH, Alyea EP, Weller E et al. Comparative outcomes of T-cell depleted and non-T-cell depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: Impact of donor lymphocyte infusion. J Clin Oncol 1999; 17:561-568.
7. Cross NC, Feng L, Chase A et al. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-1936.
8. Lin F, van Rhee F, Goldman JM, Cross NC. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996; 87: 4473-4478.
9. Clift R, Goldman J, Gratwohl A, Horowitz M. Proposals for standardized reporting of results of bone marrow transplantation for leukaemia. Bone Marrow Transplant 1989; 4: 445-448.
10. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
11. Shulman HM, Sullivan KM, Weiden P et al. Chronic graft-versus-host disease syndrome in man. A long term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
12. Kantarjian HM, O'Brien S, Cortes JE et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100: 1590-1595.
13. Olavarria E, Ottmann OG, Deininger M et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Leukemia 2003; 17: 1707-1712.
14. DeAngelo DJ, Hochberg EP, Alyea EP et al. Extended follow-up of patients treated with imatinib mesylate (Gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation. Clin Cancer Res 2004; 10: 5065-5071.
15. Conneally E, Carroll P, Neat M et al. Imatinib mesylate treatment of patients with chronic myeloid leukemia relapsing following allogeneic stem cell transplantation [abstract]. Blood 2004; 104: 4659.
16. Hughes TP, Kaeda J, Branford S et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-1432.